GeneDx Holdings Corp
For the period ended Dec 31, 2024. Filed Feb 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 20, 2025
WGS$54.83-16.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
a) The following documents are filed as a part of this Annual Report.
Consolidated financial statements: The consolidated financial statements are set forth under “Item 8. Financial Statements and Supplementary Data” of this Annual Report on Form 10-K.
Financial statement schedules: All schedules have been omitted because they are not required, not applicable, or the required information is included in the consolidated financial statements or notes thereto.
Exhibits: The exhibits listed in the accompanying Exhibit Index are filed or incorporated by reference as part of this Annual Report on Form 10-K.
Incorporated by Reference
| No. | Description of Exhibit | Form | Exhibit | Filing Date | Filed Herewith |
|---|---|---|---|---|---|
| 1.1 | Underwriting Agreement by and between GeneDx Holdings Corp. and Jefferies LLC, dated January 26, 2023. | 8-K | 1.1 | 01/30/2023 | |
| 1.2 | Sales Agreement, dated April 29, 2024, by and between GeneDx Holdings Corp. and TD Securities (USA) LLC. | 8-K | 1.1 | 04/29/2024 | |
| 2.1+ | Agreement and Plan of Merger, dated February 9, 2021, by and among CMLS, Merger Sub and Legacy Sema4, as amended by Amendment to Agreement and Plan of Merger dated May 3, 2021. | DEF14M | Annex A | 07/02/2021 | |
| 2.2 | Agreement and Plan of Merger and Reorganization, dated as of January 14, 2022, by and among, Orion Merger Sub I, Inc., Orion Merger Sub II, LLC, GeneDx, Inc., GeneDx Holding 2, Inc. and OPKO Health, Inc. | 8-K | 2.1 | 01/18/2022 | |
| 2.3+ | Amendment to Agreement and Plan of Merger and Reorganization, dated as of April 29, 2022, by and among, Sema4 Holdings Corp., Orion Merger Sub I, Inc., Orion Merger Sub II, LLC, GeneDx, Inc., GeneDx Holding 2, Inc. and OPKO Health, Inc. | 8-K | 99.2 | 05/02/2022 | |
| 3.1 | Third Amended and Restated Certificate of Incorporation of Sema4 Holdings Corp. | 8-K | 3.1 | 07/28/2021 | |
| 3.2 | First Certificate of Amendment of Restated Certificate of Incorporation of Sema4 Holdings Corp. | 8-K | 3.1 | 01/09/2023 | |
| 3.3 | Second Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of GeneDx Holdings Corp. | 8-K | 3.1 | 04/17/2023 | |
| 3.4 | Third Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of GeneDx Holdings Corp. | 8-K | 3.1 | 04/28/2023 | |
| 3.5 | Amended and Restated Bylaws of GeneDx Holdings Corp. | 8-K | 3.2 | 01/09/2023 | |
| 4.1 | Specimen Class A Common Stock Certificate. | S-1/A | 4.2 | 08/24/2020 | |
| 4.2 | Specimen Warrant Certificate. | S-1/A | 4.3 | 08/24/2020 | |
| 4.3 | Warrant Agreement, dated as of September 1, 2020, by and between CM Life Sciences, Inc. and Continental Stock Transfer & Trust Company, as warrant agent. | 8-K | 10.1 | 09/04/2020 | |
| 4.4 | Warrant to Purchase Stock, dated October 27, 2023, by and among the Company and Perceptive Credit Holdings IV, LP. | 8-K | 4.1 | 10/30/2023 | |
| 4.5 | Description of Securities. | X | |||
| 10.1 | Amended and Restated Registration Rights Agreement, dated as of July 22, 2021, by and among the Company, certain equity holders of the Company named therein and certain equity holders of Sema4 named therein. | 8-K | 10.2 | 07/28/2021 | |
| 10.2 | Form Director of and Officer Indemnification Agreement. | 8-K | 10.4 | 07/28/2021 | |
| 10.3* | GeneDx Holdings Corp. Amended and Restated 2021 Equity Incentive Plan. | 8-K | 10.1 | 04/17/2023 | |
| 10.4* | Form of Stock Option Agreement under the 2021 Equity Incentive Plan. | 8-K | 10.6 | 07/28/2021 | |
| 10.5* | Form of RSU Agreement under the 2021 Equity Incentive Plan. | 8-K | 10.7 | 07/28/2021 | |
| 10.6* | Form of Earn-Out RSU Agreement. | 8-K | 10.8 | 07/28/2021 | |
| 10.7* | 2021 Employee Stock Purchase Plan. | 8-K | 10.9 | 07/28/2021 |
| 10.8* | GeneDx Holdings Corp. 2023 Equity Inducement Plan. | 8-K | 10.1 | 07/24/2023 |
| 10.9* | Form of Option Award Agreement under the 2023 Equity Inducement Plan. | 8-K | 10.2 | 07/24/2023 |
| 10.10* | Form of Restricted Stock Unit Award Agreement under the 2023 Equity Inducement Plan. | 8-K | 10.3 | 07/24/2023 |
| 10.11 | Sub-Sublease, dated as of June 6, 2017, by and between Icahn School of Medicine at Mount Sinai and the Company, as amended July 31, 2019. | 8-K | 10.17 | 07/28/2021 |
| 10.12 | Sublease Agreement, dated as of November 8, 2019, by and between Marriott International, Inc. and the Company. | 8-K | 10.18 | 07/28/2021 |
| 10.13 | Sublease, dated as of June 1, 2017, by and between Icahn School of Medicine at Mount Sinai and the Company, as amended December 22, 2017. | 8-K | 10.19 | 07/28/2021 |
| 10.14 | Sublease, dated as of April 23, 2019, by and between Icahn School of Medicine at Mount Sinai and the Company. | 8-K | 10.20 | 07/28/2021 |
| 10.15 | Lease Agreement, dated as of January 31, 2020, by and between 1 Commercial Street Associates, LLC and the Company. | 8-K | 10.21 | 07/28/2021 |
| 10.16# | Master Services Agreement, dated as of April 2, 2018, by and among the Company, Icahn School of Medicine at Mount Sinai, The Mount Sinai Hospital, and the parties thereto, as amended July 31, 2019. | 8-K | 10.22 | 07/28/2021 |
| 10.17# | Master Services Agreement, dated as of May 10, 2018, by and between the Company and Icahn School of Medicine at Mount Sinai, as amended July 31, 2019. | 8-K | 10.23 | 07/28/2021 |
| 10.18# | Data Structuring and Curation Agreement, dated as of August 1, 2019, by and between Icahn School of Medicine at Mount Sinai and the Company, as amended March 11, 2020. | 8-K | 10.24 | 07/28/2021 |
| 10.19# | BioMe Biospecimen and Data Access Agreement, dated as of July 19, 2019, by and between Icahn School of Medicine at Mount Sinai and the Company. | 8-K | 10.25 | 07/28/2021 |
| 10.20# | Non-Exclusive Patent License Agreement, dated as of June 1, 2017, by and between the Company and Icahn School of Medicine at Mount Sinai. | 8-K | 10.26 | 07/28/2021 |
| 10.21# | Supply Agreement, dated as of June 20, 2014, by and between the Company and Illumina, Inc., and amendments thereto. | 8-K | 10.27 | 07/28/2021 |
| 10.22* | Mount Sinai Genomics, Inc. 2017 Equity Incentive Plan, as amended, and forms of equity agreements thereunder. | S-8 | 99.6 | 09/27/2021 |
| 10.23 | Loan and Security Agreement, dated as of November 15, 2021, between Silicon Valley Bank, the Company and Sema4 OpCo, Inc. | 10-Q | 10.26 | 11/15/2021 |
| 10.24 | Subscription Agreement, dated as of February 9, 2021, by and among the Company and the subscriber parties thereto. | 8-K | 10.1 | 02/11/2021 |
| 10.25 | Form of Subscription Agreement, dated as of January 14, 2022 by and among the Company and the subscriber parties thereto. | 8-K | 10.1 | 01/18/2022 |
| 10.26 | Form of Shareholder Agreement, dated as of January 14, 2022 by and among the Company and the stockholder parties identified therein. | 8-K | 10.2 | 01/18/2022 |
| 10.27 | Form of Support Agreement dated as of January 14, 2022 by and among the Company and the stockholder parties identified therein. | 8-K | 10.3 | 01/18/2022 |
| 10.28 | Form of Lock-Up Agreement, by and among the Company and the stockholder parties identified therein. | 8-K | 10.4 | 01/18/2022 |
| 10.29* | Executive Chairman Agreement, dated as of January 17, 2022, by and between the Company and Jason Ryan. | 10-K | 10.31 | 03/14/2022 |
| 10.30* | Amendment No. 1 to Executive Chairman Agreement. | 8-K | 10.1 | 04/14/2023 |
| 10.31+ | Transition Services Agreement, dated as of April 29, 2022, by and between GeneDx, Inc. and OPKO Health, Inc. | 8-K | 10.1 | 05/02/2022 |
| 10.32* | Employment Agreement, dated as of January 14, 2022, as amended April 29, 2022, by and between Sema4 Holdings Corp. and Katherine Stueland. | 8-K | 10.2 | 05/02/2022 |
| 10.33* | Employment Agreement of Kevin Feeley, dated January 14, 2022. | 10-K | 10.32 | 03/16/2023 |
| 10.34* | Amendment No. 1 to the Employment Agreement of Kevin Feeley, dated August 25, 2022. | 8-K | 10.1 | 08/26/2022 | |
| 10.35# | Amendment No. 1 to BioMe Biospecimen and Data Access Agreement, dated as of January 19, 2023, by and between Icahn School of Medicine at Mount Sinai and Sema4 OpCo, Inc. | 10-K | 10.34 | 03/16/2023 | |
| 10.36 | 2022 Replacement Promissory Note. | 10-K | 10.35 | 03/16/2023 | |
| 10.37 | Credit Agreement and Guaranty, dated October 27, 2023, by and among the Company and Perceptive Credit Holdings IV, LP. | 8-K | 10.1 | 10/30/2023 | |
| 10.38 | Security Agreement, dated October 27, 2023, by and among the Company and Perceptive Credit Holdings IV, LP. | 8-K | 10.2 | 10/30/2023 | |
| 10.39 | Form of Subscription Agreement. | 8-K | 10.1 | 01/30/2023 | |
| 10.40+ | Letter Agreement, Amendment No. 2 to Sub-Sublease, dated as of March 20, 2023, by and between Icahn School of Medicine at Mount Sinai and the Company. | 10-Q | 10.3 | 05/09/2023 | |
| 10.41* | Employment Agreement by and between Dr. Bryan Dechairo and GeneDx, LLC, dated as of October 10, 2024. | 8-K | 10.1 | 01/02/2025 | |
| 10.42* | Amendment to Form of Restricted Stock Unit Award Agreement under the 2023 Equity Inducement Plan. | X | |||
| 19.1 | Insider Trading Policy. | X | |||
| 21.1 | Subsidiaries of the Company. | X | |||
| 23.1 | Consent of Ernst & Young LLP, independent registered accounting firm for GeneDx Holdings Corp. | X | |||
| 24.1 | Power of Attorney (included on signature page to this Annual Report on Form 10-K). | X | |||
| 31.1 | Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2 | Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.1** | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.2** | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 97.1 | Policy Relating to Recovery of Erroneously Awarded Compensation. | X | |||
| 101.INS | Inline XBRL Instance Document | X | |||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | |||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | |||
| 101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document | X | |||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | |||
| 104 | Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.) | X | |||
| * | Management Contract or Compensatory Plan |
|---|---|
| ** | Furnished. |
| + | Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. |
| # | The Company has omitted portions of the exhibit as permitted under Regulation S-K Item 601(b)(10). |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.